menu
    • menu
    [{"orgOrder":0,"company":"SpyBiotech","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Virus-like-particle vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Serum Institute of India","highestDevelopmentStatusID":"7","companyTruncated":"SpyBiotech \/ Serum Institute of India"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"3P Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLPs based vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"SpyBiotech \/ SpyBiotech"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Braavos Investment Advisers","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SpyBiotech","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"SpyBiotech \/ Braavos Investment Advisers","highestDevelopmentStatusID":"4","companyTruncated":"SpyBiotech \/ Braavos Investment Advisers"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SpyBiotech \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SpyBiotech \/ Not Applicable"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SpyBiotech \/ Not Applicable"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"EBV Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"SpyBiotech \/ University of Oxford"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","graph1":"Technology","graph2":"Approved","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpyBiotech \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by SpyBiotech

    Menu

    SpyBiotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPYVLP01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SpyBiotech Completes Enrollment in Phase I Trial of SPYVLP01 for HCMV

                            Details : SpyBiotech's primary program, SPYVLP01, a candidate vaccine, is presently undergoing Phase I clinical trial evaluation with patients for the treatment of human cytomegalovirus infection.

                            Brand Name : SPYVLP01

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 23, 2024

                            Lead Product(s) : SPYVLP01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBV Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SpyBiotech And Oxford Collaborate On Epstein-Barr Virus Research And Development

                            Details : The collaboration aims to support development of a vaccine against Epstein-Barr virus (EBV) by combining Oxford’s academic research capabilities with SpyBiotech’s proprietary SPYVLP platform.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 23, 2024

                            Lead Product(s) : EBV Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPYVLP01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

                            Details : SpyBiotech's primary program, SPYVLP01, a candidate vaccine, is presently undergoing Phase I clinical trial evaluation with patients for the treatment of human cytomegalovirus infection.

                            Brand Name : SPYVLP01

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 07, 2023

                            Lead Product(s) : SPYVLP01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPYVLP01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01

                            Details : SPYVLP01, a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. There is currently no approved vaccine against HCMV.

                            Brand Name : SPYVLP01

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 20, 2023

                            Lead Product(s) : SPYVLP01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability o...

                            Details : The funding will support the development of next generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines using novel SpyVector platform. SpyVector is a platform based on recombinant adenovirus.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Braavos Investment Advisers

                            Deal Size : $32.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            SpyBiotech Raises $32.5M in Series A Funding and Appoints Lutz B. Giebel as Chairman

                            Details : Proceeds will advance the clinical development of SpyBiotech’s novel vaccine technology platform, based on its proprietary SpyCatcher/SpyTag protein “superglue” technology.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 10, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Braavos Investment Advisers

                            Deal Size : $32.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLPs based vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : 3P Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement

                            Details : SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 27, 2020

                            Lead Product(s) : VLPs based vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : 3P Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SpyBiotech

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Virus-like-particle vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Serum Institute of India

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Spy Biotech and Serum Institute of India Announce Dosed First Subjects in Phase I/II Trial of a Novel Virus-L...

                            Details : SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. The Phase I/II study has been initiated in Australia.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 08, 2020

                            Lead Product(s) : Virus-like-particle vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Serum Institute of India

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth